Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
New Tool Twice as Accurate at Predicting Antibody Resistance Among U.S. Children with Kawasaki Disease - Be part of the knowledge - ReachMD
Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease | Scientific Reports
IVIG Treatment for Kawasaki Disease | AmeriPharma™ Specialty
Kawasaki Dis Canada on X: "Approximately 10% to 20% of patients with Kawasaki disease develop recrudescent or persistent fever at least 36 hours after the end of their IVIG infusion and are
Figure 1 | Archives of Disease in Childhood
Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks | Italian Journal of Pediatrics | Full Text
Diagnostics | Free Full-Text | Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
Intravenous Immunoglobulin for the Treatment of Kawasaki Disease | Pediatric Annals
Clinical characteristics in Kawasaki disease related to intravenous... | Download Table
Kawasaki Disease: An Update on Diagnosis and Treatment - ScienceDirect
Management of Kawasaki disease | Archives of Disease in Childhood
Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease | Semantic Scholar
Understanding Kawasaki Disease
The Lancet - Kawasaki disease is a self-limited vasculitis that is the most common cause of acquired heart disease in children in developed countries. Although intravenous immunoglobulin (IVIG) is effective therapy, 10–20%
Kawasaki Kids on X: "Day 4 of Kawasaki Disease Awareness Month IVIG Treatment for Kawasaki Disease is the most widely used treatment to stop the fever and inflammation in the child's body.
Frontiers | A New Scoring System for Prediction of Intravenous Immunoglobulin Resistance of Kawasaki Disease in Infants Under 1-Year Old
RAISE Study: New evidence of Kawasaki disease's treatment
Treatment Options for Refractory Kawasaki Disease
Treat acute Kawasaki disease with aspirin plus intravenous immunoglobulin to improve coronary outcomes | SpringerLink
IJMS | Free Full-Text | Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker
Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study - The Lancet Child & Adolescent Health
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
An Overview of Kawasaki Disease
Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High‐Risk Patients With Kawasaki Disease | Journal of the American Heart Association
![PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d8f3d0e9bcb78fb7089e50d6f77d0efc0737cd69/5-Figure1-1.png "PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar")
PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar
Recommended clinical guideline for the management of Kawasaki disease... | Download Scientific Diagram
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
